Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients
Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for , the authors present a highly effective COVID-19 therapeutic combination, stemming from clinical observations. In 24 COVID-19 subjects refu...
Gespeichert in:
| Veröffentlicht in: | Future microbiology 2022-03, Vol.17 (5), p.339-350 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 350 |
|---|---|
| container_issue | 5 |
| container_start_page | 339 |
| container_title | Future microbiology |
| container_volume | 17 |
| creator | Hazan, Sabine Dave, Sonya Gunaratne, Anoja W Dolai, Sibasish Clancy, Robert L McCullough, Peter A Borody, Thomas J |
| description | Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for
, the authors present a highly effective COVID-19 therapeutic combination, stemming from clinical observations.
In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C.
All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There were no hospitalizations or deaths, less than (p |
| doi_str_mv | 10.2217/fmb-2022-0014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8826831</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2627134973</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-b985effedacb2c6bcce5400fe188cffd1e7412e18311894c2508b40d4d5a3f6d3</originalsourceid><addsrcrecordid>eNpVUctKJTEQDTKijrp0K1nOwtZUkn5thOHqzAiCG3Ub0umKN9Ivk7TYf28uV2Vc1evUOUUdQk6AnXMO5YXtm4wzzjPGQO6QAyhlkbGaw4-vHMQ--RnCM2N5BTXskX2Rg8gFsAOC19aiie4VBwyBjpam1Peb1pA1OmBL-7mLrvXzE41r9HpaqBtowATDbqHrZRrfnDmjum_mTsfRL3R193hzlUFNJx0dDjEckV2ru4DHH_GQPPy5vl_9y27v_t6sft9mRkoRs6auckz3tNo03BSNMZhLxixCVRlrW8BSAk-VAKhqaXjOqkayVra5FrZoxSG53PJOc9Nja5K2152avOu1X9Sonfo-GdxaPY2vqqp4kVgTwa8PAj--zBii6l0w2HV6wHEOihe8BCHrUiTo6f9aXyKfv02Aeguwc5w9BpNeYVBtq7ThjBtQAVMbH1XyUW18VBsfxTvogpIC</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627134973</pqid></control><display><type>article</type><title>Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients</title><source>MEDLINE</source><source>PubMed Central</source><creator>Hazan, Sabine ; Dave, Sonya ; Gunaratne, Anoja W ; Dolai, Sibasish ; Clancy, Robert L ; McCullough, Peter A ; Borody, Thomas J</creator><creatorcontrib>Hazan, Sabine ; Dave, Sonya ; Gunaratne, Anoja W ; Dolai, Sibasish ; Clancy, Robert L ; McCullough, Peter A ; Borody, Thomas J</creatorcontrib><description>Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for
, the authors present a highly effective COVID-19 therapeutic combination, stemming from clinical observations.
In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C.
All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There were no hospitalizations or deaths, less than (p < 0.002 or 0.05, respectively) background-matched CDC database controls. Triple combination therapy is safe and effective even when used in outpatients with moderate to severe symptoms.
NCT04482686 (
)</description><identifier>ISSN: 1746-0913</identifier><identifier>ISSN: 1746-0921</identifier><identifier>EISSN: 1746-0921</identifier><identifier>DOI: 10.2217/fmb-2022-0014</identifier><identifier>PMID: 35135310</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>coronavirus ; COVID ; COVID-19 Drug Treatment ; doxycycline ; Drug Therapy, Combination ; Humans ; Hypoxia - drug therapy ; ivermectin ; Ivermectin - therapeutic use ; Leprostatic Agents - therapeutic use ; SARS-CoV-2 ; Short Communication ; Treatment Outcome ; zinc</subject><ispartof>Future microbiology, 2022-03, Vol.17 (5), p.339-350</ispartof><rights>2022 Future Medicine Ltd</rights><rights>2022 Future Medicine Ltd 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-b985effedacb2c6bcce5400fe188cffd1e7412e18311894c2508b40d4d5a3f6d3</citedby><orcidid>0000-0002-6592-3776 ; 0000-0002-0997-6355 ; 0000-0002-7653-0388 ; 0000-0002-6767-614X ; 0000-0002-0519-4698</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826831/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826831/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35135310$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hazan, Sabine</creatorcontrib><creatorcontrib>Dave, Sonya</creatorcontrib><creatorcontrib>Gunaratne, Anoja W</creatorcontrib><creatorcontrib>Dolai, Sibasish</creatorcontrib><creatorcontrib>Clancy, Robert L</creatorcontrib><creatorcontrib>McCullough, Peter A</creatorcontrib><creatorcontrib>Borody, Thomas J</creatorcontrib><title>Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients</title><title>Future microbiology</title><addtitle>Future Microbiol</addtitle><description>Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for
, the authors present a highly effective COVID-19 therapeutic combination, stemming from clinical observations.
In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C.
All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There were no hospitalizations or deaths, less than (p < 0.002 or 0.05, respectively) background-matched CDC database controls. Triple combination therapy is safe and effective even when used in outpatients with moderate to severe symptoms.
NCT04482686 (
)</description><subject>coronavirus</subject><subject>COVID</subject><subject>COVID-19 Drug Treatment</subject><subject>doxycycline</subject><subject>Drug Therapy, Combination</subject><subject>Humans</subject><subject>Hypoxia - drug therapy</subject><subject>ivermectin</subject><subject>Ivermectin - therapeutic use</subject><subject>Leprostatic Agents - therapeutic use</subject><subject>SARS-CoV-2</subject><subject>Short Communication</subject><subject>Treatment Outcome</subject><subject>zinc</subject><issn>1746-0913</issn><issn>1746-0921</issn><issn>1746-0921</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUctKJTEQDTKijrp0K1nOwtZUkn5thOHqzAiCG3Ub0umKN9Ivk7TYf28uV2Vc1evUOUUdQk6AnXMO5YXtm4wzzjPGQO6QAyhlkbGaw4-vHMQ--RnCM2N5BTXskX2Rg8gFsAOC19aiie4VBwyBjpam1Peb1pA1OmBL-7mLrvXzE41r9HpaqBtowATDbqHrZRrfnDmjum_mTsfRL3R193hzlUFNJx0dDjEckV2ru4DHH_GQPPy5vl_9y27v_t6sft9mRkoRs6auckz3tNo03BSNMZhLxixCVRlrW8BSAk-VAKhqaXjOqkayVra5FrZoxSG53PJOc9Nja5K2152avOu1X9Sonfo-GdxaPY2vqqp4kVgTwa8PAj--zBii6l0w2HV6wHEOihe8BCHrUiTo6f9aXyKfv02Aeguwc5w9BpNeYVBtq7ThjBtQAVMbH1XyUW18VBsfxTvogpIC</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Hazan, Sabine</creator><creator>Dave, Sonya</creator><creator>Gunaratne, Anoja W</creator><creator>Dolai, Sibasish</creator><creator>Clancy, Robert L</creator><creator>McCullough, Peter A</creator><creator>Borody, Thomas J</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6592-3776</orcidid><orcidid>https://orcid.org/0000-0002-0997-6355</orcidid><orcidid>https://orcid.org/0000-0002-7653-0388</orcidid><orcidid>https://orcid.org/0000-0002-6767-614X</orcidid><orcidid>https://orcid.org/0000-0002-0519-4698</orcidid></search><sort><creationdate>20220301</creationdate><title>Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients</title><author>Hazan, Sabine ; Dave, Sonya ; Gunaratne, Anoja W ; Dolai, Sibasish ; Clancy, Robert L ; McCullough, Peter A ; Borody, Thomas J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-b985effedacb2c6bcce5400fe188cffd1e7412e18311894c2508b40d4d5a3f6d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>coronavirus</topic><topic>COVID</topic><topic>COVID-19 Drug Treatment</topic><topic>doxycycline</topic><topic>Drug Therapy, Combination</topic><topic>Humans</topic><topic>Hypoxia - drug therapy</topic><topic>ivermectin</topic><topic>Ivermectin - therapeutic use</topic><topic>Leprostatic Agents - therapeutic use</topic><topic>SARS-CoV-2</topic><topic>Short Communication</topic><topic>Treatment Outcome</topic><topic>zinc</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hazan, Sabine</creatorcontrib><creatorcontrib>Dave, Sonya</creatorcontrib><creatorcontrib>Gunaratne, Anoja W</creatorcontrib><creatorcontrib>Dolai, Sibasish</creatorcontrib><creatorcontrib>Clancy, Robert L</creatorcontrib><creatorcontrib>McCullough, Peter A</creatorcontrib><creatorcontrib>Borody, Thomas J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Future microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hazan, Sabine</au><au>Dave, Sonya</au><au>Gunaratne, Anoja W</au><au>Dolai, Sibasish</au><au>Clancy, Robert L</au><au>McCullough, Peter A</au><au>Borody, Thomas J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients</atitle><jtitle>Future microbiology</jtitle><addtitle>Future Microbiol</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>17</volume><issue>5</issue><spage>339</spage><epage>350</epage><pages>339-350</pages><issn>1746-0913</issn><issn>1746-0921</issn><eissn>1746-0921</eissn><abstract>Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for
, the authors present a highly effective COVID-19 therapeutic combination, stemming from clinical observations.
In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C.
All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There were no hospitalizations or deaths, less than (p < 0.002 or 0.05, respectively) background-matched CDC database controls. Triple combination therapy is safe and effective even when used in outpatients with moderate to severe symptoms.
NCT04482686 (
)</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>35135310</pmid><doi>10.2217/fmb-2022-0014</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-6592-3776</orcidid><orcidid>https://orcid.org/0000-0002-0997-6355</orcidid><orcidid>https://orcid.org/0000-0002-7653-0388</orcidid><orcidid>https://orcid.org/0000-0002-6767-614X</orcidid><orcidid>https://orcid.org/0000-0002-0519-4698</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1746-0913 |
| ispartof | Future microbiology, 2022-03, Vol.17 (5), p.339-350 |
| issn | 1746-0913 1746-0921 1746-0921 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8826831 |
| source | MEDLINE; PubMed Central |
| subjects | coronavirus COVID COVID-19 Drug Treatment doxycycline Drug Therapy, Combination Humans Hypoxia - drug therapy ivermectin Ivermectin - therapeutic use Leprostatic Agents - therapeutic use SARS-CoV-2 Short Communication Treatment Outcome zinc |
| title | Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T08%3A49%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20ivermectin-based%20multidrug%20therapy%20in%20severely%20hypoxic,%20ambulatory%20COVID-19%20patients&rft.jtitle=Future%20microbiology&rft.au=Hazan,%20Sabine&rft.date=2022-03-01&rft.volume=17&rft.issue=5&rft.spage=339&rft.epage=350&rft.pages=339-350&rft.issn=1746-0913&rft.eissn=1746-0921&rft_id=info:doi/10.2217/fmb-2022-0014&rft_dat=%3Cproquest_pubme%3E2627134973%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627134973&rft_id=info:pmid/35135310&rfr_iscdi=true |